E6-18443. Guidance for Industry: Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling and Consumer Protection Act of 2004 (Edition 4); Availability  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice of availability of guidance.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing the availability of a revised guidance document entitled “Guidance for Industry: Questions and Answers Regarding Food Allergens, including the Food Allergen Labeling and Consumer Protection Act of 2004 (Edition 4).” The guidance explains, using a question and answer format, FDA's current thinking on a number of issues related to the regulation of food allergens, including implementation of the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA).

    DATES:

    Submit written or electronic comments on the agency guidance at any time.

    ADDRESSES:

    Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/​dockets/​ecomments. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Rhonda R. Kane, Center for Food Safety and Applied Nutrition (HFS-820), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2371, or by e-mail: rhonda.kane@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    I. Background

    The FALCPA (Public Law 108-282) amends the Federal Food, Drug, and Cosmetic Act (the act) and requires that the label of a food product that is, or that contains, an ingredient that bears or contains a “major food allergen” declare the presence of the allergen as specified by FALCPA. FALCPA defines a “major food allergen” as one of eight foods or food groups or a food ingredient that contains protein derived from one of those foods or food groups. A food ingredient may be exempt from FALCPA's labeling requirements if it does not cause an allergic response that poses a risk to human health or if it does not contain allergenic protein. FALPCA's labeling requirements apply to products labeled on or after January 1, 2006.

    II. Discussion

    FDA has received numerous questions about the application of FALCPA's requirements to food products. To explain FALCPA's requirements as well as FDA's current thinking on several issues relating to the regulation of food allergens, on October 5, 2005, FDA posted on the agency's Web site the first edition of a guidance entitled “Guidance for Industry: Questions and Answers Regarding Food Allergens, including the Food Allergen Labeling and Consumer Protection Act of 2004” (http://www.cfsan.fda.gov/​~dms/​alrguid.html). This guidance was subsequently updated in December 2005 (Edition 2) and April 2006 (Edition 3). The guidance that is the subject of this document “Guidance for Industry: Questions and Answers Regarding Food Allergens, including the Food Allergen Labeling and Consumer Protection Act of 2004 (Edition 4),” responds to additional questions about FALCPA and food allergens. The revised guidance is intended to share FDA's current thinking on the additional questions presented in the guidance.

    Given the nature of the revisions to the guidance, FDA is issuing the guidance as a level 1 guidance. Consistent with FDA's good guidance practices regulation (§ 10.115 (21 CFR 10.115)), the agency will accept comments, but it is implementing the guidance document immediately, in accordance with § 10.115(g)(2), because the agency has determined that prior public participation is not feasible or appropriate. As noted, FALPCA's labeling requirements apply to products labeled on or after January 1, 2006. Clarifying FDA's current thinking on the additional issues presented by FALCPA's implementation will help facilitate the food industry's compliance with FALCPA's requirements.

    FDA expects to continue to receive questions regarding the implementation of FALCPA and the regulation of food allergens generally. The agency intends to respond to these inquires under Start Printed Page 64543§ 10.115 as promptly as possible, using a question-and-answer format. The agency believes that, at the present time, it is reasonable to maintain all responses to questions concerning food allergens and FALCPA in a single document that is periodically updated as the agency receives and responds to additional questions. The following four indicators will be employed to help users of the guidance identify revisions: (1) The guidance will be identified as a revision of a previously issued document, (2) the revision date of the guidance will appear on its cover, (3) the edition number of the guidance will be included in its title, and (4) questions and answers that have been added to the original guidance will be identified as such in the body of the guidance.

    This guidance represents the agency's current thinking on issues related to FALCPA and food allergens generally that are presented in the guidance. The guidance does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

    III. Comments

    Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this guidance at any time. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments and the guidance may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

    IV. Electronic Access

    Persons with access to the Internet may obtain the guidance document at http://www.cfsan.fda.gov/​guidance.html or http://www.fda.gov/​ohrms/​dockets/​default.htm.

    Start Signature

    Dated: October 26, 2006.

    Jeffrey Shuren,

    Assistant Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. E6-18443 Filed 11-1-06; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Published:
11/02/2006
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice of availability of guidance.
Document Number:
E6-18443
Dates:
Submit written or electronic comments on the agency guidance at any time.
Pages:
64542-64543 (2 pages)
Docket Numbers:
Docket No. 2005D-0490
PDF File:
e6-18443.pdf